A newly introduced treatment for advanced small‑cell lung cancer takes center stage in a news article that unpacks clinical trial evidence, safety signals, and care implications.
Key Takeaways
- European Commission authorized IMDYLLTRA as monotherapy for advanced small‑cell lung cancer
- DeLLphi‑304 phase 3 trial randomized 509 patients and used overall survival as primary endpoint
- Cytokine release syndrome occurred in 56.7% of treated patients across pooled safety data